The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer

Surgery (United States)

Volumn 157, Issue 5, 2015, Pages 881-887

  Dias Santos, Daniela ^a,b   Ferrone, Cristina R ^a   Zheng, Hui ^a   Lillemoe, Keith D ^a   Fernández Del Castillo, Carlos ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CHARLSON AGE COMORBIDITY INDEX; CHARLSON COMORBIDITY INDEX; CHEMORADIOTHERAPY; CHILD; FEMALE; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT DURATION; ADENOCARCINOMA; COMORBIDITY; EPIDEMIOLOGY; HEALTH STATUS INDICATOR; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; RISK ASSESSMENT; UNITED STATES; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84929047097     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2014.12.006     Document Type: Article

References (21)

1. H.A.H. Burris, M.J.M. Moore, J.J. Andersen, M.R.M. Green, M.L.M. Rothenberg, and M.R.M. Modiano Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
2. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA: A Cancer Journal for Clinicians n/a-n/a 2015
3. V. Heinemann, M. Haas, and S. Boeck Systemic treatment of advanced pancreatic cancer Cancer Treat Rev 38 2012 843 853
4. K. Garber Stromal depletion goes on trial in pancreatic cancer J Natl Cancer Inst 102 2010 448 450
5. T.A. Sohn, C.J. Yeo, J.L. Cameron, L. Koniaris, S. Kaushal, and R.A. Abrams Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators J Gastrointest Surg 4 2000 567 579
6. D.D. Hoff Von, R.K. Ramanathan, M.J. Borad, D.A. Laheru, L.S. Smith, and T.E. Wood Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial J Clin Oncol 29 2011 4548 4554
7. R. Kim FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? Lancet Oncol 12 2010 8 9
8. C.C. Hsu, C.L. Wolfgang, D.A. Laheru, T.M. Pawlik, M.J. Swartz, and J.M. Winter Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer J Gastrointest Surg 16 2012 753 761
9. Cheng H, Merika E, Syrigos KN, Saif MW. Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP J Pancreas (Online) 2011;12:334-38.
10. E.P. Kennedy, and C.J. Yeo The case for routine use of adjuvant therapy in pancreatic cancer J Surg Oncol 95 2007 597 603
11. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
12. C. Fernandez-del, Castillo V. Morales-Oyarvide, D. McGrath, J.A. Wargo, C.R. Ferrone, and S.P. Thayer Evolution of the Whipple procedure at the Massachusetts General Hospital Surgery 152 2012 S56 S63
13. P.A. Clavien, J. Barkun, M.L. de Oliveira, J.N. Vauthey, D. Dindo, and R.D. Schulick The Clavien-Dindo classification of surgical complications Ann Surg 250 2009 187 196
14. Global surgery fact sheet. (2013, May 12). Retrieved January 6, 2014, from http://www.cms.gov.
15. F. Gerstenhaber, J. Grossman, N. Lubezky, E. Itzkowitz, I. Nachmany, and R. Sever Pancreaticoduodenectomy in elderly adults: is it justified in terms of mortality, long-term morbidity, and quality of life? J Am Geriatr Soc 61 2013 1351 1357
16. J.S. Hill, Z. Zhou, J.P. Simons, S.C. Ng, T.P. McDade, and G.F. Whalen A simple risk score to predict in-hospital mortality after pancreatic resection for cancer Ann Surg Oncol 17 2010 1802 1807
17. W. D'Hoore, A. Bouckaert, and C. Tilquin Practical considerations on the use of the Charlson comorbidity index with administrative data bases J Clin Epidemiol 49 1996 1429 1433
18. S. Cai, T.S. Hong, S.I. Goldberg, C. Fernandez-del Castillo, S.P. Thayer, and C.R. Ferrone Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010 Cancer 119 2013 4196 4204
19. C.F. Jehn, L. Böning, H. Kröning, A. Pezzutto, and D. Lüftner Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer Eur J Cancer 50 2014 1269 1275
20. F.T. Kos, O. Yazici, B. Civelek, M. Seker, Z. Arik, and S. Aksoy Bewertung der Auswirkung von Begleiterkrankungen auf das Überleben mit Pankreaskrebs unter Verwendung des "Charlson Komorbiditäts Index" und der "Cumulative Illness Rating Skala" Wien Klin Wochenschr 126 2013 36 41
21. S. Nagai, T. Fujii, Y. Kodera, M. Kanda, T.T. Sahin, and A. Kanzaki Impact of operative blood loss on survival in invasive ductal adenocarcinoma of the pancreas Pancreas 40 2011 3 9